JP2021512121A5 - - Google Patents
Info
- Publication number
- JP2021512121A5 JP2021512121A5 JP2020541924A JP2020541924A JP2021512121A5 JP 2021512121 A5 JP2021512121 A5 JP 2021512121A5 JP 2020541924 A JP2020541924 A JP 2020541924A JP 2020541924 A JP2020541924 A JP 2020541924A JP 2021512121 A5 JP2021512121 A5 JP 2021512121A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- chemotherapy
- csf
- administered
- prinabulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023202765A JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2025234643A JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625290P | 2018-02-01 | 2018-02-01 | |
| US62/625,290 | 2018-02-01 | ||
| US201862713486P | 2018-08-01 | 2018-08-01 | |
| US62/713,486 | 2018-08-01 | ||
| US201862749060P | 2018-10-22 | 2018-10-22 | |
| US62/749,060 | 2018-10-22 | ||
| US201862757648P | 2018-11-08 | 2018-11-08 | |
| US62/757,648 | 2018-11-08 | ||
| PCT/US2019/015867 WO2019152530A1 (en) | 2018-02-01 | 2019-01-30 | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202765A Division JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512121A JP2021512121A (ja) | 2021-05-13 |
| JP2021512121A5 true JP2021512121A5 (https=) | 2022-02-08 |
Family
ID=67479904
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541924A Pending JP2021512121A (ja) | 2018-02-01 | 2019-01-30 | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2023202765A Pending JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2025234643A Pending JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202765A Pending JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2025234643A Pending JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210030843A1 (https=) |
| EP (1) | EP3746076A4 (https=) |
| JP (3) | JP2021512121A (https=) |
| KR (2) | KR20260023097A (https=) |
| CN (1) | CN112105363A (https=) |
| AU (1) | AU2019216305B2 (https=) |
| BR (1) | BR112020015758A2 (https=) |
| CA (1) | CA3089391A1 (https=) |
| IL (1) | IL276197A (https=) |
| SG (1) | SG11202006990TA (https=) |
| WO (1) | WO2019152530A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016229294B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| JP6969848B2 (ja) | 2015-07-13 | 2021-11-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリン組成物 |
| KR20180105685A (ko) | 2016-02-08 | 2018-09-28 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 투카레솔 또는 이의 유사체를 함유하는 조성물 |
| JP7025416B2 (ja) | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| EP4045046A4 (en) * | 2019-10-15 | 2024-01-10 | Beyondspring Pharmaceuticals Inc. | Methods and compositions for treating iron disorders |
| CN114746104A (zh) * | 2019-12-05 | 2022-07-12 | 韩美药品株式会社 | 治疗由化疗或放疗引起的中性粒细胞减少症的方法 |
| CA3186416A1 (en) * | 2020-07-17 | 2022-01-20 | John A. Barrett | Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| FI131561B1 (en) * | 2023-12-28 | 2025-06-30 | Faron Pharmaceuticals Oy | CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
| CN119371407A (zh) * | 2024-06-27 | 2025-01-28 | 青岛海合生物科技有限公司 | 一种具有抗肿瘤功效的2,5-二酮哌嗪类化合物及其在制备治疗和/或预防中性粒细胞减少症的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102378635A (zh) * | 2009-01-16 | 2012-03-14 | 特瓦制药工业有限公司 | 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂 |
| CA2926771C (en) * | 2013-10-11 | 2022-07-05 | Beyondspring Pharmaceuticals, Inc. | Cancer treatment with combination of plinabulin and taxane |
| JP7025416B2 (ja) * | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| BR112019015974A2 (pt) * | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
-
2019
- 2019-01-30 US US16/966,156 patent/US20210030843A1/en active Pending
- 2019-01-30 CN CN201980018772.9A patent/CN112105363A/zh active Pending
- 2019-01-30 KR KR1020267003258A patent/KR20260023097A/ko active Pending
- 2019-01-30 KR KR1020207024515A patent/KR20200116477A/ko not_active Ceased
- 2019-01-30 CA CA3089391A patent/CA3089391A1/en active Pending
- 2019-01-30 BR BR112020015758-9A patent/BR112020015758A2/pt unknown
- 2019-01-30 AU AU2019216305A patent/AU2019216305B2/en active Active
- 2019-01-30 EP EP19746727.7A patent/EP3746076A4/en active Pending
- 2019-01-30 JP JP2020541924A patent/JP2021512121A/ja active Pending
- 2019-01-30 WO PCT/US2019/015867 patent/WO2019152530A1/en not_active Ceased
- 2019-01-30 SG SG11202006990TA patent/SG11202006990TA/en unknown
-
2020
- 2020-07-21 IL IL276197A patent/IL276197A/en unknown
-
2023
- 2023-11-30 JP JP2023202765A patent/JP2024015120A/ja active Pending
-
2025
- 2025-12-05 JP JP2025234643A patent/JP2026026377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512121A5 (https=) | ||
| JP2024015120A5 (https=) | ||
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2016528162A5 (https=) | ||
| JP2021512149A5 (https=) | ||
| JP2009539769A5 (https=) | ||
| RU2015126661A (ru) | Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата | |
| JP2009515901A5 (https=) | ||
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| CN105497091B (zh) | 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用 | |
| CN104434939B (zh) | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 | |
| JP5976923B2 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| RU2010139840A (ru) | Комбинация противораковых агентов | |
| JP2022504760A5 (https=) | ||
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| RU2696288C2 (ru) | Способ лечения кастрационно-устойчивого рака простаты | |
| Nakao et al. | Amrubicin monotherapy for elderly patients with previously treated lung cancer | |
| CN111773388A (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
| RU2673816C1 (ru) | Способ лечения кастрационно-устойчивого рака простаты | |
| Carlson | Advanced Endometrial Cancer: Carboplatin-Paclitaxel Regimen Promising | |
| Choy et al. | Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer | |
| RU2020126600A (ru) | Композиция и способ уменьшения вызванной химиотерапией нейтропении с помощью введения плинабулина и агента г-ксф |